Sunesis and MMRC collaborate to study SNS-032 in myeloma
Sunesis and MMRC collaborate to study SNS-032 in myeloma
SOUTH SAN FRANCISCO, California-Sunesis Pharmaceuticals, Inc. and the Multiple Myeloma Research Consortium (MMRC) have entered into a collaboration to evaluate Sunesis' SNS-032 for the treatment of multiple myeloma. SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7, and 9 that inhibits both cell cycle progression and transcription.
Articles in this issue
New tobacco product alert: Camel Snus is on the loose
Blueberry punch not quite a 'knock out' blow
Texas voters listen to Lance
Cellectar opens manufacturing facility for radiolabeled CLR1404
High cost of breast MRI screening appears to be justified
Broccoli Sprouts Extract Might Lower Bladder Cancer Risk
Xeloda/Ixempra Effective in Resistant Triple-Negative Ca
Steven Rosen, MD, accepts Editor-in-Chief position for Oncology News International
Statins during RT may lower risk of prostate ca relapse
Call for congressional hearing on Provenge approval process re-ignites FDA conflict-of-interest controversy
Major policy issue lies behind ODAC's Avastin decision
Zevalin boosts PFS in advanced follicular NHL patients
Breast MRI reveals occult cancers in PBI candidates
Researchers defend NLST protocol against its critics
High-dose neoadjuvant fulvestrant tested
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
